Scientists at the University of Cambridge have created a vaccine utilizing artificial intelligence to design its core component, representing what they describe as a significant advancement in pandemic preparedness. The researchers used genetic sequences from multiple coronaviruses collected through surveillance programs and fed this data to an AI system, which generated a novel antigen capable of training the immune system to recognize and fight an entire family of viruses rather than a single strain.
The vaccine was engineered to provide protection against all coronavirus variants, including those currently circulating in animals with potential to cause human pandemics. Unlike traditional vaccines designed from current virus strains, this AI-generated approach aims to stay ahead of viral mutations and emerging threats. Researchers at the institution are simultaneously developing separate vaccines using similar technology for influenza and Ebola using animal research models.
Early human trials involving 39 participants were conducted to assess vaccine safety, with findings published in the Journal of Infection. Results indicated the vaccine produced a “modest” impact on the immune system, though researchers view the outcomes favorably. A larger second trial involving approximately 200 participants is planned to better evaluate the vaccine’s effectiveness in generating immune responses.
Experts not directly involved in the research acknowledged the potential of the AI-design approach. Scientists noted that artificial intelligence could substantially accelerate vaccine development by predicting immune system responses, potentially saving lives and enabling faster vaccine deployment globally. The Cambridge team is advancing research on universal flu vaccines that would not require annual updates and preparations for potential H5N1 bird flu emergence in human populations.
Article Attribution | Read More at Article Source
Article summary produced by Claude AI